Phathom Pharmaceuticals, Inc.
General ticker "PHAT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $585.2M (TTM average)
Phathom Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 55.9%.
Estimated limits based on current volatility of 5.8%: low 10.73$, high 12.05$
Factors to consider:
- Total employees count: 427 as of 2024
- Top business risk factors: Limited operating history, Need for additional capital, Operational and conduct risks, Dependence on key products, Market competition
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [11.22$, 27.76$]
- 2026-12-31 to 2027-12-31 estimated range: [8.75$, 22.20$]
Financial Metrics affecting the PHAT estimates:
- Negative: with PPE of -8.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -13.43 <= 0.01
- Positive: Investing cash flow per share per price, % of -0.02 > -0.63
- Positive: -3.43 < Return on assets ratio (scaled to [-100,100]) of 0
- Negative: Shareholder equity ratio, % of -169.08 <= 19.40
Short-term PHAT quotes
Long-term PHAT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.68MM | $55.25MM | $175.11MM |
| Operating Expenses | $167.99MM | $332.72MM | $335.10MM |
| Operating Income | $-167.31MM | $-277.47MM | $-159.99MM |
| Non-Operating Income | $-34.28MM | $-56.86MM | $159.99MM |
| Interest Expense | $41.97MM | $72.01MM | $68.11MM |
| R&D Expense | $49.90MM | $34.08MM | $32.78MM |
| Income(Loss) | $-201.59MM | $-334.33MM | $0.00MM |
| Profit(Loss)* | $-201.59MM | $-334.33MM | $-221.25MM |
| Stockholders Equity | $-72.76MM | $-253.58MM | $-438.17MM |
| Inventory | $1.21MM | $3.21MM | $5.52MM |
| Assets | $413.84MM | $378.32MM | $259.15MM |
| Operating Cash Flow | $-137.58MM | $-266.77MM | $-166.78MM |
| Capital expenditure | $1.63MM | $0.14MM | $0.00MM |
| Investing Cash Flow | $-1.63MM | $-0.14MM | $-0.23MM |
| Financing Cash Flow | $367.58MM | $182.77MM | $-0.29MM |
| Earnings Per Share** | $-3.93 | $-5.29 | $-3.03 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.